Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 2/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | GCGR | P47871 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 7/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | TP53 | P04637 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1854401 | 0.83 | ALOX5AP (0.51) | EGFRCDK9CCNT1ALOX5APFEN1 | |
| SCHEMBL1850151 | 0.83 | HSP90AA1 (0.59) | CDK9CCNT1HSP90AA1HSP90AB1CHRNA7 | |
| SCHEMBL2988060 | 0.80 | CLK4 (0.43) | EGFRCDK9CCNT1HSP90AA1HSP90AB1 | |
| SCHEMBL4431846 | 0.77 | CYP1A2 (0.44) | HSP90AA1HSP90AB1CHRNA7CLK4CYP1A2 | |
| SCHEMBL2985808 | 0.75 | BRD4 (0.50) | CDK9CCNT1CLK4CYP1A2CYP2C19 | |
| SCHEMBL14661164 | 0.75 | KMO (0.68) | KMO | |
| SCHEMBL2993281 | 0.73 | HSP90AA1 (0.44) | EGFRCDK9CCNT1HSP90AA1HSP90AB1 | |
| SCHEMBL4103611 | 0.72 | CYP1A2 (0.60) | CDK9CCNT1CLK4CYP1A2CYP2C19 | |
| SCHEMBL8227740 | 0.72 | ADRA2A (0.59) | ALOX5APFEN1HSP90AA1CHRNA7CYP1A2 | |
| SCHEMBL3632568 | 0.72 | IRAK4 (0.50) | ALOX5APFEN1MAPK14GCGRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130338147-A1 | 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-12-19 | — | — | US | disclosed |
| US-8507498-B2 | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| US-8507498-B2 | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| EP-2137166-B1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2012-05-30 | — | — | EP | disclosed |
| US-20110306602-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | US | disclosed |
| US-20110306602-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | US | disclosed |
| US-20110306602-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | US | disclosed |
| EP-2137166-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | Ingenium Pharmaceuticals GmbH (DE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008129080-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338147-A1 | 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | CDK2, CDK6, CDK5 | EGFR 1885/4885CDK9 8/4885CCNT1 45/4885 |
| US-20110306602-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | CDK6, CDK2, CDK1 | EGFR 1589/4885CDK9 7/4885CCNT1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.